Trade Mark Journal No.2025/044 31 October 2025
WO0000001881489 (5,42,44)
Office of origin: United States of America
Date of International Registration:18 August 2025
Date of designation in the UK:
18 August 2025

International priority date claimed: 24 April 2025
(United States of America)
(99152854)
- Class 5
- Pharmaceuticals for the treatment of rare genetic diseases; pharmaceuticals for the treatment of musculo-skeletal disorders; pharmaceuticals for the treatment of skeletal dysplasia.
- Class 42
- Research and development of drugs in the fields of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; scientific research for medical purposes in the fields of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; clinical research in the fields of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; scientific research and development of pharmaceuticals for the treatment of rare diseases, musculo-skeletal disorders, and skeletal dysplasia.
- Class 44
- Providing medical information; providing medical information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; providing medical information via a web site; providing information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; providing information in the field of pharmaceuticals via a web site.
Tyra Biosciences, Inc.
Representative: Kevin M. Bovard Baker & Hostetler LLP, 1735 Market Street, Suite 3300, Philadelphia PA 19103, UNITED STATES OF AMERICA